Soleno maintains a focused pipeline strategy centered on rare metabolic and endocrine diseases, capitalizing on high unmet medical needs where treatment options are severely limited. The company leverages diazoxide chemistry to target KATP channels in multiple tissue types, providing a differentiated mechanism with potential applications across multiple rare disease indications beyond Prader-Willi Syndrome.
Cyborg Score Rationale
While Soleno achieved a significant FDA approval and generated $98.7M in trailing revenue, recent class action investigations and short-seller allegations regarding VYKAT XR safety and pricing have created substantial legal and reputational risks. The company faces near-term execution risks during U.S. and European launches, though regulatory approval validates its core approach.
Top Insights
VYKAT XR received FDA approval in early 2025, marking Soleno's transition from clinical-stage to commercial company and first product generating commercial revenue ($98.7M TTM)
Multiple law firms launched class action investigations in late 2025 following Scorpion Capital short report alleging safety, pricing, and disclosure concerns regarding VYKAT XR
Market cap of $2.15B as of February 11, 2026, with significant valuation uncertainty reflected in wide analyst price target spreads ($46-$465 per share)
Company experienced recent CFO transition (James Mackaness retirement, Jennifer Fulk appointment) amid heightened scrutiny and operational challenges
Named Competitors
Obesity and Appetite Regulation Drugs — GLP-1 receptor agonists for metabolic disorders
Endocrine and Metabolic Therapeutics — Broad rare disease and endocrine portfolio
Hypothalamic Obesity Programs — Emerging competitor in metabolic rare disease space
Recent Developments
(Feb 2026) Stock price at $40.05 with $2.15B market cap; company preparing to report Q4 2025 and full-year 2025 results
(Late 2025) Class action investigations launched by major law firms due to short report allegations regarding VYKAT XR safety and pricing
(Early 2025) FDA approved VYKAT XR (diazoxide choline) for Prader-Willi Syndrome, enabling commercial launch
Open the full interactive Soleno Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.